Accelerate to discover

Back to filter

Related topics

ACCELA Educational webinar series: Unlocking Spatial Biology with RareCyte Orion Technology

RareCyte

Nov 16, 2022

Discover full slide, high-plex biomarker quantitation with the all-in-one spatial biology...

Practical aspects of an imaging study: live in vivo scanning

MOLECUBES

Nov 11, 2022

In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...

Advances in Leukemia research using shear flow and Bioflux system

Fluxion Biosciences

May 24, 2022

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...

In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers

MOLECUBES

Mar 9, 2022

Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...

Dec 8, 2022

Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing

Curiox

Oct 11, 2021

Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...

Dec 8, 2022

Blood-Brain Barrier (BBB) - Pathophysiology in ischemic stroke

RWD

Aug 27, 2021

In-depth Understanding of Blood-Brain Barrier (BBB)

Show all topics (10)

Next generation karyotyping: detecting cancer-associated structural variants using optical maps

Apr 19, 2017

James Broach, PhD, Penn State Hershey, Pennsylvania, United States.

Identification of structural variants (SVs) is critical to the prognosis of acute myeloid leukemia (AML) and other hematologic malignancies. SVs are not readily identified by next generation sequencing methods and are currently diagnosed by cytogenetics, an intrinsically low resolution tool. Dr. James Broach from Penn State Hershey will discuss a new method for determining large SVs as a clinical tool for evaluating AML and other cancer genomes using Bionano optical mapping. Dr. Broach has applied this technology for detection of SVs in a variety of cancer cell lines and directly from leukemia patient blood samples.  In all cases, they have identified all the SVs reported by classic cytogenetic analysis and, in addition, a large number of translocations, deletions and insertions not observed by cytogenetics.

Register now

Webinar

Get more info

Regina Fillerová

Field application specialist

Regina

Fillerová

+420 731 127 718

Send Message

Brand profile

BioNano Genomics

A revolutionary NanoChannel technology for Genome mapping of extremely long DNA without amplification, providing long-range contiguity and eliminating PCR bias.

Related products

Genome maps of extremely long DNA without amplification, providing long-range contiguity and eliminating PCR bias

show detail

Saphyr provides rapid, high-throughput, long-range genome mapping with unmatched structural variation discovery capabilities

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey